Trial Profile
A multi-national, multi-centre, double-blind, randomised, parallel group study to compare the safety and efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for ten days in subjects with Clostridium Difficile-associated diarrhea (CDAD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Fidaxomicin (Primary) ; Vancomycin
- Indications Clostridium difficile infections; Diarrhoea
- Focus Registrational; Therapeutic Use
- Sponsors Optimer Pharmaceuticals
- 26 Apr 2013 Australian Therapeutic Goods Administration approved fidaxomicin for Clostridium difficile infection based on this trial, according to an Optimer Pharmaceuticals media release.
- 29 Jun 2012 Companies added in the association field as reported by EudraCT.
- 16 Jun 2012 Results presented at the 15th International Congress on Infectious Diseases.